Avenir Award Program for Chemistry and Pharmacology of Substance Use Disorders (DP1- Clinical Trial Not Allowed) (344128)

From US Department of Health & Human Services: National Institutes of Health (NIH)

The National Institutes of Health (NIH), a part of the U.S. Department of Health and Human Services, is the nation’s medical research agency — making important discoveries that improve health and save lives.

Type of Support

Overview

The goal of this Funding Opportunity Announcement (FOA) is to promote the entry of early-stage investigators into the fields of chemistry and pharmacology related to substance use disorders. The grant aims to support researchers in the initial stages of their career, particularly those who may not have the preliminary data required for more substantial grants like an R01. It focuses on high-impact research that has the potential to shape the future leaders in substance disorder research. The grant encourages the application of advanced methods and technologies in identifying new targets, mechanisms, pathways, probes, and optimized compounds for the development of novel therapeutic agents for substance use disorders. The funding cap is set at $300,000 in Direct Costs annually for a period of up to five years.

Eligibility

Organization's Location
est in
Program Location
do
Organization Type
up to 1.5M

Submission

Schedule
Step 1: aute duis laborum
Application deadline
Dec 19, 2024
Step 2: ad adipisicing (magna culpa)

Similar grants